A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis.
about
Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds EnA Randomized, Placebo-Controlled Study of SRT2104, a SIRT1 Activator, in Patients with Moderate to Severe PsoriasisLeflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study.Evaluation of efalizumab using safe psoriasis control.Reliability, validity and responsiveness to change of the Patient Report of Extent of Psoriasis Involvement (PREPI) for measuring body surface area affected by psoriasisOral curcumin in the treatment of moderate to severe psoriasis vulgaris: A prospective clinical trial.Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting.Adalimumab: an anti-TNF agent for the treatment of psoriatic arthritis.Ichthyotherapy as alternative treatment for patients with psoriasis: a pilot study.Depletion of antigen-presenting cells by clodronate liposomes reverses the psoriatic skin phenotype in KC-Tie2 mice.Relationship between retinal sensitivity and disease activity in patients with psoriasis vulgaris.Serum levels of TNF-α, IL-12/23p40, and IL-17 in plaque psoriasis and their correlation with disease severity.Psoriasis assessment tools in clinical trials.Efficacy of combining oral Chinese herbal medicine and NB-UVB in treating psoriasis vulgaris: a systematic review and meta-analysis.Assessing Cutaneous Psoriasis Activity Using FDG-PET: Nonattenuation Corrected Versus Attenuation Corrected PET Images.Current severe psoriasis and the rule of tens.Vitamin D receptor gene polymorphisms and haplotypes (Apa I, Bsm I, Fok I, Taq I) in Turkish psoriasis patientsImmunobiologics in the treatment of psoriasis.Treatment of severe psoriasis with infliximab.Novel immunobiologics for psoriasis.Comparative efficacy of biologics in psoriasis: a review.Phytotherapy in the management of psoriasis: a review of the efficacy and safety of oral interventions and the pharmacological actions of the main plants.Patient involvement in outcome measures for psoriatic arthritis.Novel methods of measuring clinical outcomes from psoriasis and psoriatic arthritis clinical trials.Systematic review of cost-effectiveness analyses of treatments for psoriasis.Tofacitinib for the treatment of moderate-to-severe psoriasis.Quality of life: a research gap in teledermatology.Time, PASI and DLQI of psoriasis patients who "drop out" of clinical trials on etanercept due to "lack of efficacy" - a pooled analysis from ten clinical trials.Association Between Skin and Aortic Vascular Inflammation in Patients With Psoriasis: A Case-Cohort Study Using Positron Emission Tomography/Computed Tomography.Increased MicroRNA-1266 levels as a biomarker for disease activity in psoriasis vulgaris.Combination of skin, joint and quality of life outcomes with etanercept in psoriasis and psoriatic arthritis in the PRESTA trial.A randomized, double-blind, placebo-controlled trial of the effect of monthly vitamin D supplementation in mild psoriasis.Psoriasis: Epidemiology, clinical features, co-morbidities, and clinical scoring.Non-inferiority margins employed in clinical trials in Japan.Oral Curcumin (Meriva) Is Effective as an Adjuvant Treatment and Is Able to Reduce IL-22 Serum Levels in Patients with Psoriasis VulgarisEffect of Oral PUVAsol on the Quality of Life in Indian Patients Having Chronic Plaque Psoriasis.Pattern of response in patients with moderate-to-severe psoriasis treated with etanercept.The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients.Cost effectiveness of moderate to severe psoriasis therapy with etanercept and ustekinumab in the United States.A pilot study examining mindfulness-based cognitive therapy in psoriasis.
P2860
Q26862017-E042584F-4E49-42DC-AF9B-D57324301CB9Q28550785-61060104-701E-4BE0-82D9-F242BD7E7C33Q31034753-E1A11C18-501B-4E30-A023-303920B2DE35Q33258048-8D13EC99-9EA1-455D-8009-4E56D80F2BE0Q33879351-41EF951B-0F2D-488C-9344-5811C3F51EEEQ34038554-56D277FA-54E1-439F-9F50-B85029E4A1FBQ34196035-BD6BB581-B8C8-4634-895B-69C724925E10Q34562148-A9AA9704-3B3F-46DB-B190-AC942181F755Q34573366-35547352-E0EB-4ACC-96B9-14A25FA2F227Q34634463-002EEFC8-D3D2-4503-A641-09B79948ED86Q35029128-0202B740-C957-408D-B16D-F605AA7BBD44Q35155926-68DC6C54-486F-4B0D-AFE2-C6395F2E7DD9Q35579443-AF75DE60-7869-4265-B628-3AD7D54E0B98Q36094590-487B9259-F559-4594-907B-B85AB357B447Q36108233-465EBA1C-027B-4B04-B13E-4523488DCC09Q36124195-93941093-5AFC-4738-9D7C-E67CBE7C402EQ36576962-AFB4EC99-C12E-4E94-A92D-BAC83C2B3A3DQ36743142-F2D19316-A17B-4496-90D7-5762620E9737Q37098135-267028CF-7F17-4CDB-A017-9D482954BFF8Q37664478-BDE705C5-99D5-4093-BDA3-D8E51B49530DQ38042475-81FEFAD4-5D75-440C-9C62-E90BE9310068Q38164204-800CDAF1-D92B-4C2F-8187-2BEF4C596AD9Q38195568-4CFB727E-B4FE-453B-A447-808C443A4841Q38211315-111F04EC-14B3-4B4B-94AC-6F0A9F8F2E68Q38283299-82DE0B96-7167-43D5-A957-6AF805C11A42Q38349779-11379CDF-7D88-4E40-BC19-46F9E061CE5DQ38558139-47385301-608D-4E9B-AF56-4D01D622A0DDQ38644270-E93F4B0F-B98B-4389-A277-816EFA9232C3Q38676598-A98D445A-4B45-4031-82CF-9993D93FDFB7Q38846063-71FDC010-1253-47BA-B4ED-E8F4E6B28C90Q39837952-9DB6342F-B1AE-44A2-8BC0-420DDE4C10F4Q40066888-DFF97CBE-4E75-4649-8763-E82D6F834B27Q40419030-0CF749B4-8A29-402C-A4A3-941EAD206CFDQ41366996-8523195C-5070-4363-A45D-4D854F534F09Q41460287-60524A45-A32B-48B1-9B73-DE35CF5AB007Q41889404-17EB0ECB-FDBD-446F-9793-B89D0E03FE45Q44773623-53E34B85-BE23-41E3-9724-BA049D381A52Q46356347-E0919550-C80B-453D-BC01-85953CE64E0DQ46945261-65E9C6D0-DFFD-4DD1-B700-F5BD29A41841Q48081441-016C4BFA-C783-44B0-A100-346F1930BC4C
P2860
A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
A 50% reduction in the Psorias ...... n the assessment of psoriasis.
@en
A 50% reduction in the Psoriasis Area and Severity Index
@nl
type
label
A 50% reduction in the Psorias ...... n the assessment of psoriasis.
@en
A 50% reduction in the Psoriasis Area and Severity Index
@nl
prefLabel
A 50% reduction in the Psorias ...... n the assessment of psoriasis.
@en
A 50% reduction in the Psoriasis Area and Severity Index
@nl
P2093
P1476
A 50% reduction in the Psorias ...... in the assessment of psoriasis
@en
P2093
Alan Menter
Christopher S Carlin
Gerald G Krueger
James G Krueger
P304
P356
10.1016/J.JAAD.2003.09.014
P407
P577
2004-06-01T00:00:00Z